Hawaiian Eye and Retina 2022

You care about your patients; they trust your judgement.

Fagron Sterile Services US (FSS) is excited to join the 2022 Hawaiian Eye Conference and share more about our leading 503B outsourcing services. While Fagron serves 60 countries and growing over the last 30 years, FSS got its start 20 years ago in the ophthalmic pharmaceutical compounding space, formerly known as JCB Laboratories.

Now vertically integrated with the global leader dedicated to pharmaceutical compounding (Fagron), FSS has expanded its portfolio and produced innovative new products through cGMP compliant operations like the only sterile LET gel and a revolutionary Avastin® syringe in collaboration with West Pharmaceuticals.

Learn More and Download a Full Product Catalog.

A MESSAGE FROM HAWAIIAN EYE PROGRAM DIRECTOR, DR. RICHARD LINDSTROM

"The Hawaiian Eye meeting has been special to me since 1982, but when I saw how many faculty, attendees and industry joined us for our delayed Hawaiian Eye & Retina meeting in May, I now realize how much it means to our entire ophthalmic community.

There is so much good that comes out of this week-long event. Our speakers are of the brightest minds in ophthalmology who have valuable pearls of wisdom to share. We connect with attendees both at the podium and on a personal level around the resort, sometimes meeting each other’s spouse and children, and often becoming life-long friends. We’ve grown this meeting into a family, and I couldn’t be prouder to be a part of its growth and success.

Next year will be my 50th year in ophthalmology, the 40th year of Ocular Surgery News/Healio, my 30th anniversary as Chief Medical Editor of OSN/Healio and the 45th Annual Hawaiian Eye & Retina Meeting. I’d say we have a lot to celebrate! Please join me on Hawaii’s Big Island from January 15-21, 2022 where you can expect a great experience – the highest quality education and networking in one of the world’s most beautiful locations."

MORE ABOUT FAGRON STERILE SERVICES

Fagron Sterile Services US (FSS), a top-tier DEA and FDA-registered 503B Outsourcing Provider, produces reliable supply of high-quality sterile medications with cGMP compliant operations for patient-focused healthcare facilities across North America.

FSS' team employs expertise in legal and regulatory compliance, pharmaceutical manufacturing and repackaging, leveraging industry leading automation, advanced environmental monitoring and sophisticated in-house quality testing labs. Batches are validated to support Beyond Use Dating (BUD) and only released after successful sterility, particulate matter and potency testing are complete.

FSS offers a broad product portfolio across Critical Care, like ready-to-administer operating room anesthesia, Ophthalmics, Pain Management and other Specialty Presentations, and holds Integrated Delivery Network (IDN) agreements within all major GPOs.